Equities analysts forecast that Scholar Rock Holding Co. (NASDAQ:SRRK – Get Rating) will announce ($0.68) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Scholar Rock’s earnings, with the lowest EPS estimate coming in at ($1.16) and the highest estimate coming in at ($0.16). Scholar Rock posted earnings of ($0.76) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 10.5%. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Scholar Rock will report full year earnings of ($3.96) per share for the current fiscal year, with EPS estimates ranging from ($4.37) to ($3.18). For the next fiscal year, analysts forecast that the business will report earnings of ($4.30) per share, with EPS estimates ranging from ($5.99) to ($3.20). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that cover Scholar Rock.
Scholar Rock (NASDAQ:SRRK – Get Rating) last posted its quarterly earnings results on Monday, March 7th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.05) by $0.08. Scholar Rock had a negative net margin of 700.46% and a negative return on equity of 64.57%. The business had revenue of $4.05 million for the quarter, compared to analyst estimates of $4.33 million. During the same quarter last year, the business posted ($2.81) EPS.
Shares of NASDAQ:SRRK traded down $1.44 during mid-day trading on Monday, reaching $11.18. 34,537 shares of the company’s stock were exchanged, compared to its average volume of 278,643. The firm has a market cap of $394.62 million, a price-to-earnings ratio of -3.11 and a beta of 0.24. The firm’s fifty day simple moving average is $15.40. The company has a quick ratio of 4.13, a current ratio of 4.13 and a debt-to-equity ratio of 0.28. Scholar Rock has a twelve month low of $11.35 and a twelve month high of $44.95.
Institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in Scholar Rock by 4.1% during the 4th quarter. BlackRock Inc. now owns 2,288,026 shares of the company’s stock valued at $56,835,000 after buying an additional 89,921 shares during the period. Wellington Management Group LLP increased its stake in Scholar Rock by 124.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,276,488 shares of the company’s stock valued at $42,150,000 after purchasing an additional 708,831 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Scholar Rock by 25.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,273,193 shares of the company’s stock valued at $31,626,000 after acquiring an additional 262,130 shares during the last quarter. State Street Corp boosted its holdings in shares of Scholar Rock by 4.1% during the 4th quarter. State Street Corp now owns 1,246,877 shares of the company’s stock valued at $30,972,000 after acquiring an additional 49,411 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Scholar Rock during the 4th quarter valued at about $14,267,000. 82.42% of the stock is owned by institutional investors.
About Scholar Rock (Get Rating)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
- Get a free copy of the StockNews.com research report on Scholar Rock (SRRK)
- 3 Undervalued Stocks The Insiders Are Buying
- The Market For Gamestop Is Near A Turning Point
- PayPal Stock is Still Ready for Bargain Hunting
- It’s Personal: 3 Personal Care Stocks to Own in Volatile Markets
- Conagra Stock Has More Room to Grow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.